SOPHiA GENETICS (Nasdaq: SOPH), today announced an agreement with Hiroshima 
University, one of the top public universities in Hiroshima City, Japan, to 
support their molecular profiling by next-generation sequencing (NGS) in 
investigating the pathogenic variants causing different blood cancer disorders.

Logo - https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg 

Hiroshima University is home to one of the largest university research 
institutes in the field of radiation biomedical science in Japan. With NGS for 
myeloid testing not widely available in Japan, a group of Hiroshima University 
researchers tapped the SOPHiA DDM Platform [ 
https://c212.net/c/link/?t=0&l=en&o=3449864-1&h=992472028&u=https%3A%2F%2Fwww.sophiagenetics.com%2Ftechnology%2F&a=SOPHiA+DDM+Platform 
] to assist with the clinical utility of NGS tests for myeloid malignancies. 
Hiroshima University aimed to establish a framework where the NGS-based testing 
would become a routine part of clinical diagnosis for myeloid neoplasms.

Following the adoption of the SOPHiA DDM Platform, Masatoshi Nishizawa from 
Hiroshima University presented a research case study at the 83rd Annual Meeting 
of Japanese Society of Hematology (Sendai, September 23-25, 2021). Leveraging 
the SOPHiA DDM Platform's unique algorithmic capabilities, the researchers from 
Hiroshima University detailed their experience with the first 24 samples of 
myeloid solution collected and analyzed as part of a research project to 
evaluate the clinical utility of NGS testing for myeloid malignancies. The 
evaluation showed that the SOPHiA DDM platform's unique capabilities in support 
of NGS testing were both useful and feasible in identifying druggable targets 
and making precise diagnosis and prognosis to help benefit more patients in 
Japan. The work of Hiroshima University has since been shared with Japanese 
laboratories and clinicians, and the university aims to continue its evaluation 
with additional samples over the next 12 months.

"SOPHiA GENETICS is committed to improving patient outcomes through the 
practice of data driven medicine. We work with several oncohematology centers 
around the world and are now eager to start supporting the Japanese 
oncohematology network of hospitals. The more data we compute, the more benefit 
we bring to all our users to ultimately accelerate the democratization of 
data-driven-medicine," said Jurgi Camblong, co-founder and CEO of SOPHiA 
GENETICS.

"To make a personalized treatment in the real-world practice of oncohematology 
prevail, the sophistication of diagnostic gene panels is strongly desired," 
said Tatsuo Ichinohe, Director of the Department of Hematology and Oncology at 
Hiroshima University Hospital. "SOPHiA GENETICS' Myeloid Plus Solution is one 
of the best examples I have ever seen in terms of its ease of use and wide 
coverage."

SOPHiA GENETICS' partnership with Hiroshima University follows the company's 
March 2021 announcement [ 
https://c212.net/c/link/?t=0&l=en&o=3449864-1&h=3015334536&u=https%3A%2F%2Fwww.sophiagenetics.com%2Fpress-releases%2Fsophia-genetics-and-hitachi-announce-collaboration-to-advance-data-driven-precision-medicine%2F&a=March+2021+announcement 
] of a long-term collaboration agreement with Hitachi, Ltd. To bring clinical, 
genomic, and real-world insights to more Japanese healthcare providers and 
pharmaceutical and biopharmaceutical companies. In partnership with Hitachi, 
discussions continue with additional Japanese institutions who may also benefit 
from SOPHiA GENETICS for oncohematological cancer research.

About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to 
establishing the practice of data-driven medicine as the standard of care and 
for life sciences research. It is the creator of the SOPHiA DDM(TM) Platform, a 
cloud-based SaaS platform capable of analyzing data and generating insights 
from complex multimodal data sets and different diagnostic modalities. The 
SOPHiA DDM(TM) Platform and related solutions, products and services are 
currently used by more than 780 hospital, laboratory, and biopharma 
institutions globally. For more information, visit SOPHiAGENETICS.COM [ 
https://c212.net/c/link/?t=0&l=en&o=3449864-1&h=3529243215&u=https%3A%2F%2Fwww.sophiagenetics.com%2F&a=SOPHiAGENETICS.COM 
], or connect on Twitter [ 
https://c212.net/c/link/?t=0&l=en&o=3449864-1&h=2748024951&u=https%3A%2F%2Ftwitter.com%2FSOPHiAGENETICS&a=Twitter 
], LinkedIn [ 
https://c212.net/c/link/?t=0&l=en&o=3449864-1&h=1540961280&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsophiagenetics&a=LinkedIn 
] and Instagram [ 
https://c212.net/c/link/?t=0&l=en&o=3449864-1&h=382237363&u=https%3A%2F%2Fwww.instagram.com%2Fsophia_genetics&a=Instagram 
]. Where others see data, we see answers. 

SOPHiA GENETICS products are for Research Use Only and not for use in 
diagnostic procedures, unless specified otherwise. The information in this 
press release is about products that may or may not be available in different 
countries and, if applicable, may or may not have received approval or market 
clearance by a governmental regulatory body for different indications for use. 
Please contact support@sophiagenertics.com to obtain the appropriate product 
information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking 
statements. All statements other than statements of historical facts contained 
in this press release, including statements regarding our future results of 
operations and financial position, business strategy, products and technology, 
as well as plans and objectives of management for future operations, are 
forward-looking statements. Forward-looking statements are based on our 
management's beliefs and assumptions and on information currently available to 
our management. Such statements are subject to risks and uncertainties, and 
actual results may differ materially from those expressed or implied in the 
forward-looking statements due to various factors, including those described in 
our filings with the U.S. Securities and Exchange Commission. No assurance can 
be given that such future results will be achieved. Such forward-looking 
statements contained in this press release speak only as of the date hereof . 
We expressly disclaim any obligation or undertaking to update these 
forward-looking statements contained in this press release to reflect any 
change in our expectations or any change in events, conditions, or 
circumstances on which such statements are based, unless required to do so by 
applicable law. No representations or warranties (expressed or implied) are 
made about the accuracy of any such forward-looking statements.


SOURCE  SOPHiA GENETICS

CONTACT: Eliza Bamonti, ebamonti@sophiagenetics.com